Monoclonal gammopathy of undetermined significance

Robert A. Kyle, S Vincent Rajkumar

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

Significant advances have been made in our understanding of the natural history, pathogenesis, mechanisms of progression and prognosis of monoclonal gammopathy of undetermined significance (MGUS). Although the overall incidence of MGUS progression is 1 per year, it is now possible to more accurately predict the risk of progression based on a new risk-stratification model. However, it is still hard to design chemopreventive trials given that the absolute risk of progression per year is low, even in the high-risk group. Therefore, further improvements in estimating the risk of progression are needed. Roughly 50% of MGUS may originate from primary translocation events at the heavy-chain immunoglobulin locus at chromosome 14q32. In most of the remaining MGUS patients, the initiating event is associated with genomic instability that results in hyperdiploidy of certain odd numbered chromosomes. Cytogenetically distinct subtypes of MGUS may carry significant differences in the risk of progression to malignancy. New markers, such as measures of bone marrow angiogenesis and circulating plasma cells may be additional prognostic factors. A better understanding of the mechanisms underlying the transition of normal plasma cells to the MGUS phenotype, and the transition of MGUS to myeloma or related malignancy, will help identify new risk factors for progression and new targets for chemopreventive interventions.

Original languageEnglish (US)
Pages (from-to)573-589
Number of pages17
JournalBritish Journal of Haematology
Volume134
Issue number6
DOIs
StatePublished - Sep 2006

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Plasma Cells
Chromosomes
Immunoglobulin Heavy Chains
Polyploidy
Genomic Instability
Natural History
Neoplasms
Bone Marrow
Phenotype
Incidence

Keywords

  • Amyloidosis
  • Lymphoma
  • Macroglobulinaemia
  • Monoclonal gammopathy of undetermined significance
  • Myeloma
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Monoclonal gammopathy of undetermined significance. / Kyle, Robert A.; Rajkumar, S Vincent.

In: British Journal of Haematology, Vol. 134, No. 6, 09.2006, p. 573-589.

Research output: Contribution to journalArticle

@article{215a223f56e44fd9ba1950783644332f,
title = "Monoclonal gammopathy of undetermined significance",
abstract = "Significant advances have been made in our understanding of the natural history, pathogenesis, mechanisms of progression and prognosis of monoclonal gammopathy of undetermined significance (MGUS). Although the overall incidence of MGUS progression is 1 per year, it is now possible to more accurately predict the risk of progression based on a new risk-stratification model. However, it is still hard to design chemopreventive trials given that the absolute risk of progression per year is low, even in the high-risk group. Therefore, further improvements in estimating the risk of progression are needed. Roughly 50{\%} of MGUS may originate from primary translocation events at the heavy-chain immunoglobulin locus at chromosome 14q32. In most of the remaining MGUS patients, the initiating event is associated with genomic instability that results in hyperdiploidy of certain odd numbered chromosomes. Cytogenetically distinct subtypes of MGUS may carry significant differences in the risk of progression to malignancy. New markers, such as measures of bone marrow angiogenesis and circulating plasma cells may be additional prognostic factors. A better understanding of the mechanisms underlying the transition of normal plasma cells to the MGUS phenotype, and the transition of MGUS to myeloma or related malignancy, will help identify new risk factors for progression and new targets for chemopreventive interventions.",
keywords = "Amyloidosis, Lymphoma, Macroglobulinaemia, Monoclonal gammopathy of undetermined significance, Myeloma, Prognosis",
author = "Kyle, {Robert A.} and Rajkumar, {S Vincent}",
year = "2006",
month = "9",
doi = "10.1111/j.1365-2141.2006.06235.x",
language = "English (US)",
volume = "134",
pages = "573--589",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Monoclonal gammopathy of undetermined significance

AU - Kyle, Robert A.

AU - Rajkumar, S Vincent

PY - 2006/9

Y1 - 2006/9

N2 - Significant advances have been made in our understanding of the natural history, pathogenesis, mechanisms of progression and prognosis of monoclonal gammopathy of undetermined significance (MGUS). Although the overall incidence of MGUS progression is 1 per year, it is now possible to more accurately predict the risk of progression based on a new risk-stratification model. However, it is still hard to design chemopreventive trials given that the absolute risk of progression per year is low, even in the high-risk group. Therefore, further improvements in estimating the risk of progression are needed. Roughly 50% of MGUS may originate from primary translocation events at the heavy-chain immunoglobulin locus at chromosome 14q32. In most of the remaining MGUS patients, the initiating event is associated with genomic instability that results in hyperdiploidy of certain odd numbered chromosomes. Cytogenetically distinct subtypes of MGUS may carry significant differences in the risk of progression to malignancy. New markers, such as measures of bone marrow angiogenesis and circulating plasma cells may be additional prognostic factors. A better understanding of the mechanisms underlying the transition of normal plasma cells to the MGUS phenotype, and the transition of MGUS to myeloma or related malignancy, will help identify new risk factors for progression and new targets for chemopreventive interventions.

AB - Significant advances have been made in our understanding of the natural history, pathogenesis, mechanisms of progression and prognosis of monoclonal gammopathy of undetermined significance (MGUS). Although the overall incidence of MGUS progression is 1 per year, it is now possible to more accurately predict the risk of progression based on a new risk-stratification model. However, it is still hard to design chemopreventive trials given that the absolute risk of progression per year is low, even in the high-risk group. Therefore, further improvements in estimating the risk of progression are needed. Roughly 50% of MGUS may originate from primary translocation events at the heavy-chain immunoglobulin locus at chromosome 14q32. In most of the remaining MGUS patients, the initiating event is associated with genomic instability that results in hyperdiploidy of certain odd numbered chromosomes. Cytogenetically distinct subtypes of MGUS may carry significant differences in the risk of progression to malignancy. New markers, such as measures of bone marrow angiogenesis and circulating plasma cells may be additional prognostic factors. A better understanding of the mechanisms underlying the transition of normal plasma cells to the MGUS phenotype, and the transition of MGUS to myeloma or related malignancy, will help identify new risk factors for progression and new targets for chemopreventive interventions.

KW - Amyloidosis

KW - Lymphoma

KW - Macroglobulinaemia

KW - Monoclonal gammopathy of undetermined significance

KW - Myeloma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=33747480248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747480248&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2006.06235.x

DO - 10.1111/j.1365-2141.2006.06235.x

M3 - Article

VL - 134

SP - 573

EP - 589

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -